CL2018000426A1 - Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de métodos electroquímicos - Google Patents

Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de métodos electroquímicos

Info

Publication number
CL2018000426A1
CL2018000426A1 CL2018000426A CL2018000426A CL2018000426A1 CL 2018000426 A1 CL2018000426 A1 CL 2018000426A1 CL 2018000426 A CL2018000426 A CL 2018000426A CL 2018000426 A CL2018000426 A CL 2018000426A CL 2018000426 A1 CL2018000426 A1 CL 2018000426A1
Authority
CL
Chile
Prior art keywords
naphthyridine
carboxamide
methoxyphenyl
dihydro
ethoxy
Prior art date
Application number
CL2018000426A
Other languages
English (en)
Inventor
Johannes Platzek
Kathrin Gottfried
Jens Assmann
Giulio Lolli
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2018000426A1 publication Critical patent/CL2018000426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B15/00—Operating or servicing cells
    • C25B15/08—Supplying or removing reactants or electrolytes; Regeneration of electrolytes
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/23—Oxidation
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/25—Reduction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Electrochemistry (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2018000426A 2015-08-21 2018-02-16 Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de métodos electroquímicos CL2018000426A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182040 2015-08-21
EP15182042 2015-08-21

Publications (1)

Publication Number Publication Date
CL2018000426A1 true CL2018000426A1 (es) 2018-07-20

Family

ID=56694167

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000426A CL2018000426A1 (es) 2015-08-21 2018-02-16 Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de métodos electroquímicos

Country Status (31)

Country Link
US (1) US10392384B2 (es)
EP (1) EP3337801B1 (es)
JP (1) JP6843120B2 (es)
KR (1) KR20180043305A (es)
CN (1) CN108137587B (es)
AU (1) AU2016311135C1 (es)
CA (1) CA2995949A1 (es)
CL (1) CL2018000426A1 (es)
CO (1) CO2018001759A2 (es)
DK (1) DK3337801T3 (es)
ES (1) ES2739907T3 (es)
HK (1) HK1252212A1 (es)
HR (1) HRP20191476T1 (es)
HU (1) HUE044678T2 (es)
IL (1) IL257522B (es)
JO (1) JOP20160185B1 (es)
LT (1) LT3337801T (es)
MX (1) MX367959B (es)
NZ (1) NZ739993A (es)
PE (1) PE20180555A1 (es)
PL (1) PL3337801T3 (es)
PT (1) PT3337801T (es)
RS (1) RS59086B1 (es)
RU (1) RU2715226C2 (es)
SG (1) SG11201801378VA (es)
SI (1) SI3337801T1 (es)
TW (1) TWI725044B (es)
UA (1) UA124418C2 (es)
UY (1) UY36863A (es)
WO (1) WO2017032678A1 (es)
ZA (1) ZA201801867B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560922A1 (de) * 2018-04-24 2019-10-30 Bayer Aktiengesellschaft Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester
JP2022514782A (ja) * 2018-12-24 2022-02-15 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 化合物の製造、その新しい塩形態および治療的使用
CN110195239B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种多氯甲基吡啶衍生物电化学脱氯制备醛、酸的方法
CN110195238B (zh) * 2019-04-15 2020-08-14 浙江工业大学 一种三氯甲基吡啶衍生物电化学脱氯制备酰胺的方法
CN111910206B (zh) * 2019-05-07 2023-03-10 中国科学技术大学 一种合成3-氰基取代的咪唑并[1,5-a]喹啉类化合物的方法
PE20221420A1 (es) * 2019-10-17 2022-09-20 Bayer Ag Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
IL292192A (en) * 2019-10-17 2022-06-01 Bayer Ag Process for the preparation of (2-cyanoethyl(4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxylate By separating the racemate using tartaric acid esters and diastereomers
JOP20220089A1 (ar) * 2019-10-17 2023-01-30 Bayer Ag عملية لتحضير 2-سيانو إثيل (4s)-4-(4-سيانو-2-مثوكسي فنيل)-5-إثوكسي-2، 8-ثنائي مثيل-1، 4-ثنائي هيدرو-1، 6-نفثيريدين-3-كربوكسيلات بفصل المركبات الراسيمية بواسطة إسترات حمض طرطريك صنوية فراغية
TW202214624A (zh) 2020-06-16 2022-04-16 德商拜耳廠股份有限公司 藉由催化不對稱漢斯（ｈａｎｔｚｓｃｈ）酯還原法進行之製備（４ｓ）－４－（４－氰基－２－甲氧基苯基）－５－乙氧基－２，８－二甲基－１，４－二氫－１，６－㖠啶－３－羧醯胺的方法
CN113214248B (zh) * 2021-04-13 2022-04-26 湖南南新制药股份有限公司 一种1,4-二氢-1,6-萘啶衍生物、药物组合物及其用途
CN113897631B (zh) * 2021-10-24 2023-05-09 昆明学院 电化学合成吡啶-2-酮衍生物的方法
CN114149427A (zh) * 2021-12-18 2022-03-08 上海鼎雅药物化学科技有限公司 非奈利酮及其中间体的合成方法
CN114605410B (zh) * 2022-04-06 2023-12-29 浙江科聚生物医药有限公司 一种非奈利酮原料药的制备方法
WO2023205164A1 (en) 2022-04-18 2023-10-26 Teva Pharmaceuticals International Gmbh Processes for the preparation of finerenone
CN115583866A (zh) * 2022-08-30 2023-01-10 上海厚博生物科技有限公司 一种用非奈利酮对映体制备非奈利酮的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
US20080312209A1 (en) 2005-07-12 2008-12-18 Glaxo Group Limited Piperazine Heteroaryl Derivatives as Gpr38 Agonists
DE102007009494A1 (de) * 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung

Also Published As

Publication number Publication date
TW201722943A (zh) 2017-07-01
KR20180043305A (ko) 2018-04-27
JP2018523697A (ja) 2018-08-23
HUE044678T2 (hu) 2019-11-28
SG11201801378VA (en) 2018-03-28
JOP20160185B1 (ar) 2021-08-17
US20180244668A1 (en) 2018-08-30
PE20180555A1 (es) 2018-04-02
SI3337801T1 (sl) 2019-08-30
UA124418C2 (uk) 2021-09-15
AU2016311135A1 (en) 2018-03-15
ZA201801867B (en) 2019-10-30
US10392384B2 (en) 2019-08-27
CA2995949A1 (en) 2017-03-02
CN108137587A (zh) 2018-06-08
RS59086B1 (sr) 2019-09-30
MX2018002236A (es) 2018-03-23
RU2018109762A3 (es) 2019-12-18
NZ739993A (en) 2022-05-27
DK3337801T3 (da) 2019-08-19
WO2017032678A1 (de) 2017-03-02
IL257522A (en) 2018-04-30
IL257522B (en) 2020-04-30
PL3337801T3 (pl) 2019-10-31
HRP20191476T1 (hr) 2019-11-15
HK1252212A1 (zh) 2019-05-24
RU2018109762A (ru) 2019-09-23
LT3337801T (lt) 2019-08-12
AU2016311135B2 (en) 2020-09-10
JP6843120B2 (ja) 2021-03-17
RU2715226C2 (ru) 2020-02-26
AU2016311135C1 (en) 2022-10-13
TWI725044B (zh) 2021-04-21
MX367959B (es) 2019-09-12
UY36863A (es) 2017-03-31
EP3337801B1 (de) 2019-06-12
PT3337801T (pt) 2019-08-05
ES2739907T3 (es) 2020-02-04
CN108137587B (zh) 2020-10-23
CO2018001759A2 (es) 2018-02-28
EP3337801A1 (de) 2018-06-27
BR112018003334A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
CL2018000426A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y para la recuperación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida por medio de métodos electroquímicos
IL286165B1 (en) Pyrimidine or pyridine compounds, a method for their preparation and pharmaceutical uses thereof
DK3159409T3 (da) Antisense-nukleinsyre til anvendelse i behandlingen af duchenne muskeldystrofi
DK3328992T3 (da) Fremgangsmåder til fremstilling af decellulariserede vævs-scaffolds
IL250239A0 (en) A method for the preparation of (4)-4-(s4-cyano-2-methoxyphenyl)-5-ethoxy-8,2-dimethyl-4,1-dihydro-6,1-naphthyridine-3-carboxamide and its purification for use as an active pharmaceutical ingredient
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
ZA201801947B (en) Compounds as dna probes, methods and applications thereof
GB201403216D0 (en) Nucleic acid sample preparation
GB201621271D0 (en) Method for nucleic acid depletion
GB201405226D0 (en) Nucleic acid preparation method
DK3337800T3 (da) Fremgangsmåde til fremstilling af (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxamid og dets oprensning til anvendelse som farmaceutisk aktivt stof
GB201413318D0 (en) Nucleic acid sample preparation
GB201418621D0 (en) Improved nucleic acid sample preparation using concatenation
EP3204395A4 (en) Novel precatalyst scaffolds for cross-coupling reactions, and methods of making and using same
DK3155422T4 (da) Demaskering af endotoksiner i opløsning
CL2018000428A1 (es) Procedimiento de preparación de los metabolitos de (4s) y (4r)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridina-3-carboxamida y uso de los mismos
DK3533791T3 (da) Fremgangsmåde til fremstilling af 3-methyl-2-thiophencarboxylsyre
GB201508280D0 (en) Analyte detection using nanopores
GB201406580D0 (en) Nucleic Acid Sample preparation